Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2788545 | 0.80 | DPP4 (0.35) | CTSCDPP4FAPDPP8DPP9 | |
| SCHEMBL2788539 | 0.80 | DPP4 (0.35) | CTSCDPP4FAPDPP8DPP9 | |
| SCHEMBL27677392 | 0.80 | DPP4 (0.40) | CTSCDPP4FAPDPP8DPP9 | |
| SCHEMBL4089174 | 0.78 | TERT (0.31) | CTSC | |
| SCHEMBL25831466 | 0.77 | DPP4 (0.39) | CTSCDPP4FAPDPP8DPP9 | |
| SCHEMBL31748278 | 0.77 | DPP4 (0.39) | CTSCDPP4FAPDPP8DPP9 | |
| SCHEMBL8502895 | 0.77 | DPP4 (0.40) | DPP4DPP8DPP7 | |
| SCHEMBL8502890 | 0.77 | DPP4 (0.40) | DPP4DPP8DPP7 | |
| SCHEMBL31106879 | 0.74 | MME (0.42) | CTSCDPP4FAPDPP8DPP9 | |
| SCHEMBL22542531 | 0.74 | MME (0.42) | CTSCDPP4FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | CTSC 619/4885DPP4 552/4885FAP 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.